{"url":"https://lda.senate.gov/api/v1/filings/3512a77d-4a6d-429d-bb1c-91fcce98bb49/","filing_uuid":"3512a77d-4a6d-429d-bb1c-91fcce98bb49","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2023,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/3512a77d-4a6d-429d-bb1c-91fcce98bb49/print/","filing_document_content_type":"text/html","income":null,"expenses":"110000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Kacy Hutchison","dt_posted":"2024-01-22T18:50:51-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"3141 Stevens Creek Blvd. #40547","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"San Jose","registrant_state":"CA","registrant_zip":"95117","registrant":{"id":401107080,"url":"https://lda.senate.gov/api/v1/registrants/401107080/","house_registrant_id":55819,"name":"LYKOS THERAPEUTICS","description":null,"address_1":"3141 Stevens Creek Blvd. #40547","address_2":null,"address_3":null,"address_4":null,"city":"San Jose","state":"CA","state_display":"California","zip":"95117","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KRISTIN RAND","contact_telephone":"+1 206-550-7385","dt_updated":"2026-01-21T08:43:32.263305-05:00"},"client":{"id":53389,"url":"https://lda.senate.gov/api/v1/clients/53389/","client_id":53389,"name":"LYKOS THERAPEUTICS","general_description":"Healthcare/pharmaceuticals","client_government_entity":null,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2022-11-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues related to MDMA Assisted Therapy research, education and capacity building to support potential for treating mental health challenges, including PTSD. H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, regarding therapeutics research and development.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140785,"prefix":null,"prefix_display":null,"first_name":"KACY","nickname":null,"middle_name":null,"last_name":"HUTCHISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"Issues related to MDMA Assisted Therapy research, education and capacity building to support potential for treating mental health challenges, including PTSD. H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, regarding therapeutics research and development.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140785,"prefix":null,"prefix_display":null,"first_name":"KACY","nickname":null,"middle_name":null,"last_name":"HUTCHISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to MDMA Assisted Therapy research, education and capacity building to support potential for treating mental health challenges, including PTSD. H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, regarding therapeutics research and development. H.R. 4531 / S. 3393, Support for Patients and Communities Reauthorization Act, regarding issues related to pharmaceutical distribution.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140785,"prefix":null,"prefix_display":null,"first_name":"KACY","nickname":null,"middle_name":null,"last_name":"HUTCHISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Issues related to MDMA Assisted Therapy research, education and capacity building to support potential for treating mental health challenges, including PTSD. H.R. 4366 / S. 2127, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, regarding therapeutics research and development.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140785,"prefix":null,"prefix_display":null,"first_name":"KACY","nickname":null,"middle_name":null,"last_name":"HUTCHISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}